You are here: Home » PTI Stories » National » News
Business Standard

Sun Pharma receives EIR for its Halol facility

Press Trust of India  |  New Delhi 

Drug Industries today said it has received establishment inspection report (EIR) from the US regulator for its facility in

The company has received from the Food and Drug Administration (USFDA) for the inspection conducted at the facility during the period February 12-23, 2018, said in a filing to BSE.

"The agency concluded that the inspection is now closed and the issues contained in the warning letter issued in December 2015 have been addressed," it added.

Commenting on the development, MD Dilip Shanghvi said, "This is an important development for We remain committed to following the highest levels of quality and 24x7 cGMP compliance at all our globally."

In February, the USFDA had issued three observations after inspecting the facility. The company had said it was preparing the response to the observations.

Sun Pharma had received a warning letter from the USFDA over violation of manufacturing norms in its facility at in in end of 2015.

This followed inspection of the facility in September 2014 by FDA inspectors.

Shares of Industries today closed at Rs 540.50 per scrip on BSE, up 1.03 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, June 12 2018. 17:55 IST